The recipient of "The American Glaucoma Society – Thom J. Zimmerman, MD, PhD Memorial Award, Supported by Valeant Ophthalmics" has been announced as Thasarat S. Vajaranant, MD, of the University of Illinois at Chicago. Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC, worked with the American Glaucoma Society (AGS) to establish the award in memory of Dr. Thom J. Zimmerman, the developer of the glaucoma medication timolol maleate (TIMOPTIC).
The Zimmerman award consists of an unrestricted grant of $40,000 to support Dr. Vajaranant's clinical research study, “A Feasibility Study to Assess the Accuracy of Self-reported Glaucoma Outcomes and Participant Interest in Ancillary Glaucoma Studies as Part of the Women's Health Initiative (WHI) Extension.” The WHI is a large-scale national study cohort, providing a unique opportunity to build a large multiracial and multiethnic database regarding the genotype-phenotype influence on primary open-angle glaucoma. The award recipient was selected by the AGS Research Committee with final approval of the AGS Board of Directors.
Dr. Zimmerman was Emeritus Professor and Chair of the Department of Ophthalmology and Visual Sciences and Emeritus Professor of the Department of Pharmacology and Toxicology at the University of Louisville. He was best known for the development of drugs for treatment of glaucoma including timolol. With his partner, Chris Paterson, he spearheaded the building of the addition to the Kentucky Lions Eye Center and the Rounsavall Eye Clinic.
Indications for TIMOPTIC in OCUDOSE
Preservative-free TIMOPTIC in OCUDOSE is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC in OCUDOSE may be used when a patient is sensitive to the preservative in TIMOPTIC (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.